DE1291336B - Verfahren zur Herstellung von 3ª‡-(N, N-Dimethylaminoacetoxy)-11-oxo-20, 20-bis-(nitratomethyl)-21-nitrato-5ª‰-pregnan und Saeureadditionssalzen desselben - Google Patents
Verfahren zur Herstellung von 3ª‡-(N, N-Dimethylaminoacetoxy)-11-oxo-20, 20-bis-(nitratomethyl)-21-nitrato-5ª‰-pregnan und Saeureadditionssalzen desselbenInfo
- Publication number
- DE1291336B DE1291336B DER35155A DER0035155A DE1291336B DE 1291336 B DE1291336 B DE 1291336B DE R35155 A DER35155 A DE R35155A DE R0035155 A DER0035155 A DE R0035155A DE 1291336 B DE1291336 B DE 1291336B
- Authority
- DE
- Germany
- Prior art keywords
- bis
- oxo
- nitratomethyl
- nitrato
- dimethylaminoacetoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 20
- 230000008569 process Effects 0.000 title claims description 15
- -1 N, N-dimethylaminoacetoxy Chemical group 0.000 title claims description 13
- 150000003839 salts Chemical class 0.000 title claims description 7
- 239000002253 acid Substances 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 239000000047 product Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- HSMPDPBYAYSOBC-UHFFFAOYSA-N khellin Chemical compound O1C(C)=CC(=O)C2=C1C(OC)=C1OC=CC1=C2OC HSMPDPBYAYSOBC-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- AZHFOZMCFQVLBA-UHFFFAOYSA-N 2-methyl-4h-chromen-3-one Chemical compound C1=CC=C2CC(=O)C(C)OC2=C1 AZHFOZMCFQVLBA-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SXFPNMRWIWIAGS-UHFFFAOYSA-N Khellin Natural products COC1C2CCOC2C(OC)C3OC(C)CC(=O)C13 SXFPNMRWIWIAGS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229960002801 khellin Drugs 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- AFIBSLOONYVLOV-UHFFFAOYSA-N [N].ClO Chemical compound [N].ClO AFIBSLOONYVLOV-UHFFFAOYSA-N 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR897748A FR1380418A (fr) | 1962-05-16 | 1962-05-16 | Nouveau stéroïde aminé et procédé de préparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1291336B true DE1291336B (de) | 1969-03-27 |
Family
ID=8779059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DER35155A Pending DE1291336B (de) | 1962-05-16 | 1963-05-10 | Verfahren zur Herstellung von 3ª‡-(N, N-Dimethylaminoacetoxy)-11-oxo-20, 20-bis-(nitratomethyl)-21-nitrato-5ª‰-pregnan und Saeureadditionssalzen desselben |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3132072A (en:Method) |
| AT (1) | AT254404B (en:Method) |
| BE (1) | BE632446A (en:Method) |
| CH (1) | CH416616A (en:Method) |
| DE (1) | DE1291336B (en:Method) |
| DK (1) | DK110053C (en:Method) |
| ES (1) | ES288015A1 (en:Method) |
| FR (2) | FR1380418A (en:Method) |
| GB (1) | GB1001198A (en:Method) |
| NL (2) | NL292462A (en:Method) |
-
0
- BE BE632446D patent/BE632446A/xx unknown
- NL NL121525D patent/NL121525C/xx active
- NL NL292462D patent/NL292462A/xx unknown
-
1962
- 1962-05-16 FR FR897748A patent/FR1380418A/fr not_active Expired
-
1963
- 1963-05-03 CH CH561063A patent/CH416616A/fr unknown
- 1963-05-07 US US278745A patent/US3132072A/en not_active Expired - Lifetime
- 1963-05-08 DK DK216663AA patent/DK110053C/da active
- 1963-05-08 GB GB18267/63A patent/GB1001198A/en not_active Expired
- 1963-05-10 DE DER35155A patent/DE1291336B/de active Pending
- 1963-05-14 ES ES288015A patent/ES288015A1/es not_active Expired
- 1963-05-16 AT AT396963A patent/AT254404B/de active
- 1963-09-30 FR FR906456A patent/FR2053M/fr active Active
Non-Patent Citations (1)
| Title |
|---|
| None * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2053M (fr) | 1963-09-30 |
| DK110053C (da) | 1968-09-09 |
| US3132072A (en) | 1964-05-05 |
| NL121525C (en:Method) | |
| NL292462A (en:Method) | |
| BE632446A (en:Method) | |
| FR1380418A (fr) | 1964-12-04 |
| ES288015A1 (es) | 1963-07-16 |
| AT254404B (de) | 1967-05-26 |
| GB1001198A (en) | 1965-08-11 |
| CH416616A (fr) | 1966-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2832587A1 (de) | Neue vincaminolester und verfahren zur herstellung dieser verbindungen | |
| DE2517293C2 (de) | Neue Cardenolid-β-Glykoside, ihre Herstellung und Verwendung | |
| DE1291336B (de) | Verfahren zur Herstellung von 3ª‡-(N, N-Dimethylaminoacetoxy)-11-oxo-20, 20-bis-(nitratomethyl)-21-nitrato-5ª‰-pregnan und Saeureadditionssalzen desselben | |
| DE655404C (de) | Verfahren zur Herstellung eines Esters des Pseudotropins | |
| DE1468554C (de) | 20 beta tert Amino 3 alpha hydroxy (bzw acyloxy) 5 beta pregnane bzw de ren Salze sowie Verfahren zu ihrer Her stellung | |
| DE2648284C2 (en:Method) | ||
| DE1468554B1 (de) | 20beta-tert.-Amino-3alpha-hydroxy-(bzw.-acyloxy)-5beta-pregnane bzw. deren Salze sowie Verfahren zu ihrer Herstellung | |
| DE936592C (de) | Verfahren zur Herstellung eines blut- und harnzuckersenkenden Praeparates aus trioxyflavonglukosidhaltigen Pflanzenteilen | |
| CH526526A (de) | Verfahren zur Herstellung eines neuen 6a-Methyl-19-nor-progesterons | |
| CH638817A5 (de) | Nicht-glykosidische theophyllin-zucker-derivate und verfahren zu ihrer herstellung. | |
| DE1793685C3 (de) | Helveticosidderivate | |
| DE925047C (de) | Verfahren zur Umlagerung von Acetyldigitoxin-ª‰ in Acetyldigitoxin-ª‡ | |
| DE875655C (de) | Verfahren zur Darstellung von Testosteron | |
| DE1793686C3 (de) | Helveticosidderivate und diese enthaltende Arzneimittel | |
| DE2307795C3 (de) | 11 beta 17alpha, 21 Trihydroxy-6 | |
| DE1129490B (de) | Verfahren zur Herstellung des N-(5-Nitro-2-furfuryliden)-3-amino-3, 4, 5, 6-tetrahydro-1, 3-oxazinons-(2) | |
| AT354659B (de) | Verfahren zur herstellung von neuen prostaglandinderivaten | |
| DE1445626A1 (de) | Verfahren zur Gewinnung von Alkaloiden | |
| DE1942854A1 (de) | Neue substituierte 3-Amino-4-halogensydnonimine | |
| DE1145175B (de) | Verfahren zur Gewinnung von Rescidin aus Pflanzen der Rauwolfiaarten und zur Herstellung von dessen Salzen | |
| DE1173093B (de) | Verfahren zur Herstellung von 3ª-Amino-11-keto-20, 20-bis-hydroxymethyl-5ª-pregnanbzw. von Salzen desselben | |
| DE1242224B (de) | Verfahren zur Gewinnung des neuen Alkaloids Paravallarin, d. i. (20S)-3beta-N-Methylamino-20-hydroxy-5-pregnen-18-saeure-18, 20-lacton | |
| DE1203770B (de) | Verfahren zur Herstellung von 3alpha-Hydroxy-11-oxo-21, 21-bis-(hydroxymethyl)-5beta-an bzw. einfacher oder mehrfacher Ester desselben | |
| DE1203769B (de) | Verfahren zur Herstellung von therapeutisch wirksamen N, N'-substituierten 20-Aminomethyl-21-amino-steroiden bzw. Salzen derselben | |
| DE1215704B (de) | Verfahren zur Herstellung von 3alpha, 21-Dihydroxy-11-oxo-20-hydroxymethyl-5beta-pregnan und Estern desselben |